生物制剂治疗银屑病复发的研究现状

doi:10.35541/cjd.20230301

Abstract

Abstract: 【Abstract】 Psoriasis is a chronic, recurrent, systemic, inflammatory disease. Over the past 20 years, with the development and application of biologics targeting tumor necrosis factor （TNF） or TNF receptors, interleukin-17A （IL-17A） or IL-17A receptors, IL-23, and others, significant progress has been made in the treatment of psoriasis. However, recurrence remains a major challenge in the management of psoriasis after discontinuation of biologic therapy or during maintenance treatment. This review summarizes the recurrence of psoriasis following biologic treatment and proposes comprehensive management recommendations to prevent its recurrence.

Key words: Psoriasis, Recurrence, Biological agents, Tumor necrosis factor inhibitors, Interleukin inhibitors, Patient care management, Universal precautions

Wang Wenqiu, Li Chengxin, Wang Rui. Biologics for the treatment of psoriasis relapse: current status[J]. Chinese Journal of Dermatology,2025,e20230301. doi:10.35541/cjd.20230301

References ［50］

［1］	Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis［J］. Lancet, 2007,370（9583）:263⁃271. doi: 10.1016/S0140⁃6736（07）61128⁃3.
［2］	Brownstone ND, Hong J, Mosca M, et al. Biologic treatments of psoriasis: an update for the clinician［J］. Biologics, 2021,15:39⁃51. doi: 10.2147/BTT.S252578.
［3］	Committee on Psoriasis, Dermatology and Venereology Branch of the Chinese Medical Association. Expert consensus on the Treat⁃to⁃Target strategy for psoriasis with biological agents in China （simplified edition）［J］. Int J Dermatol Venerol, 2024,7（2）:61⁃69. doi: 10.1097/JD9.0000000000000300.
［4］	Tian D, Lai Y. The relapse of psoriasis: mechanisms and mysteries［J］. JID Innov, 2022,2（3）:100116. doi: 10.1016/j.xjidi.2022.100116.
［5］	Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies［J］. J Allergy Clin Immunol, 2017,140（3）:645⁃653. doi: 10.1016/j.jaci.2017.07.004.
［6］	Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis［J］. Int J Mol Sci, 2020,21（20）:7488. doi: 10.3390/ijms21207488.
［7］	Li SJ, Perez⁃Chada LM, Merola JF. TNF inhibitor⁃induced psoriasis: proposed algorithm for treatment and management［J］. J Psoriasis Psoriatic Arthritis, 2019,4（2）:70⁃80. doi: 10.1177/2475530318810851.
［8］	Gerriets V, Goyal A, Khaddour K. Tumor necrosis factor inhibitors［M］. Treasure Island （FL）: StatPearls Publishing, 2022.
［9］	Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phaseⅢ, multicentre, double⁃blind trial［J］. Lancet, 2005,366（9494）:1367⁃1374. doi: 10.1016/S0140⁃6736（05）67566⁃6.
［10］	Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phaseⅡ randomized, placebo⁃controlled trial with a re⁃treatment extension［J］. Br J Dermatol, 2012,167（1）:180⁃190. doi: 10.1111/j.1365⁃2133.2012.10941.x.
［11］	Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phaseⅢ trial［J］. J Am Acad Dermatol, 2008,58（1）:106⁃115. doi: 10. 1016/j.jaad.2007.09.010.
［12］	Tse MT. IL⁃17 antibodies gain momentum［J］. Nat Rev Drug Discov, 2013,12（11）:815⁃816. doi: 10.1038/nrd4152.
［13］	Bartlett HS, Million RP. Targeting the IL⁃17⁃T（H）17 pathway［J］. Nat Rev Drug Discov, 2015,14（1）:11⁃12. doi: 10.1038/nrd4518.
［14］	Branisteanu DE, Cojocaru C, Diaconu R, et al. Update on the etiopathogenesis of psoriasis （review）［J］. Exp Ther Med, 2022,23（3）:201. doi: 10.3892/etm.2022.11124.
［15］	Lowes MA, Suárez⁃Fariñas M, Krueger JG. Immunology of psoriasis［J］. Annu Rev Immunol, 2014,32:227⁃255. doi: 10.1146/annurev⁃immunol⁃032713⁃120225.
［16］	Crowley JJ, Warren RB, Cather JC. Safety of selective IL⁃23p19 inhibitors for the treatment of psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1676⁃1684. doi: 10.1111/jdv.15653.
［17］	Ghazawi FM, Mahmood F, Kircik L, et al. A review of the efficacy and safety for biologic agents targeting il⁃23 in treating psoriasis with the focus on tildrakizumab［J］. Front Med （Lausanne）, 2021,8:702776. doi: 10.3389/fmed.2021.702776.
［18］	Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti⁃interleukin⁃23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phaseⅢ, double⁃blinded, placebo⁃ and active comparator⁃controlled VOYAGE 1 trial［J］. J Am Acad Dermatol, 2017,76（3）:405⁃417. doi: 10.1016/j.jaad.2016.11.041.
［19］	Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate⁃to⁃severe psoriasis （ECLIPSE）: results from a phase 3, randomised controlled trial［J］. Lancet, 2019,394（10201）:831⁃839. doi: 10.1016/S0140⁃6736（19）31773⁃8.
［20］	Gordon KB, Feldman SR, Koo JY, et al. Definitions of measures of effect duration for psoriasis treatments［J］. Arch Dermatol, 2005,141（1）:82⁃84. doi: 10.1001/archderm.141.1.82.
［21］	Khemis A, Kelati A, Montaudié H, et al. Successful treatment of severe psoriasis relapse with secukinumab （interleukin 17 A inhibitor） after abrupt brodalumab （interleukin 17 receptor inhibitor） discontinuation: a retrospective study evaluating long⁃term efficacy and safety［J］. J Am Acad Dermatol, 2018,79（4）:758⁃760. doi: 10.1016/j.jaad.2018.03.027.
［22］	Masson Regnault M, Konstantinou MP, Khemis A, et al. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients［J］. J Eur Acad Dermatol Venereol, 2017,31（9）:1491⁃1496. doi: 10.1111/jdv.14387.
［23］	Ortonne JP, Taïeb A, Ormerod AD, et al. Patients with moderate⁃to⁃severe psoriasis recapture clinical response during re⁃treatment with etanercept［J］. Br J Dermatol, 2009,161（5）:1190⁃1195. doi: 10.1111/j.1365⁃2133.2009.09238.x.
［24］	Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate⁃to⁃severe psoriasis［J］. N Engl J Med, 2010,362（2）:118⁃128. doi: 10.1056/NEJMoa 0810652.
［25］	Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial［J］. JAMA Dermatol, 2020,156（6）:649⁃658. doi: 10.1001/jamadermatol.2020.0723.
［26］	Warren RB, Carrascosa JM, Fumero E, et al. Time to relapse after tildrakizumab withdrawal in patients with moderate⁃to⁃severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:919⁃927. doi: 10.1111/jdv.16964.
［27］	Kimball AB, Papp KA, Reich K, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phaseⅢ studies［J］. Br J Dermatol, 2020,182（6）:1359⁃1368. doi: 10.1111/bjd.18484.
［28］	Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum il⁃23⁃regulated il⁃17 and il⁃22 in psoriasis: VOYAGE 2 study［J］. J Invest Dermatol, 2019,139（12）:2437⁃2446.e1. doi: 10.1016/j.jid.2019.05.016.
［29］	Rivera R, Martorell A, López A, et al. Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study［J］. J Eur Acad Dermatol Venereol, 2021,35（1）:e65⁃e67. doi: 10. 1111/jdv.16809.
［30］	Chiu HY, Hui RC, Tsai TF, et al. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8⁃year multicenter study［J］. J Am Acad Dermatol, 2023,88（1）:71⁃78. doi: 10.1016/j.jaad.2019. 01.035.
［31］	Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment⁃as⁃needed versus fixed⁃interval maintenance regimen for moderate to severe plaque psoriasis:a randomized, double⁃blind, noninferiority trial （SCULPTURE）［J］. J Am Acad Dermatol, 2015,73（1）:27⁃36. doi: 10.1016/j.jaad.2015.04.011.
［32］	Blauvelt A, Reich K, Warren RB, et al. Secukinumab re⁃initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis［J］. Br J Dermatol, 2017,177（3）:879⁃881. doi: 10.1111/bjd.15656.
［33］	Blauvelt A, Papp KA, Sofen H, et al. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis［J］. J Eur Acad Dermatol Venereol, 2017,31（6）:1004⁃1013. doi: 10.1111/jdv.14163.
［34］	Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy［J］. Br J Dermatol, 2011,164（2）:434⁃441. doi: 10.1111/j.1365⁃2133.2010.10139.x.
［35］	Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque⁃type psoriasis: a randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2004,51（4）:534⁃542. doi: 10.1016/j.jaad.2004.02.021.
［36］	Demirbaş A, Kurtipek GS, Tunçez A, et al. The role of cystatin⁃C and fetuin⁃A in the determination of early atherosclerotic risk in psoriasis patients［J］. Dermatol Ther, 2020,33（6）:e13898. doi: 10.1111/dth.13898.
［37］	Telfer NR, Chalmers RJ, Whale K, et al. The role of streptococcal infection in the initiation of guttate psoriasis［J］. Arch Dermatol, 1992,128（1）:39⁃42.
［38］	Dileepan T, Linehan JL, Moon JJ, et al. Robust antigen specific th17 T cell response to group A Streptococcus is dependent on IL⁃6 and intranasal route of infection［J］. PLoS Pathog, 2011,7（9）:e1002252. doi: 10.1371/journal.ppat.1002252.
［39］	Rendon A, Schäkel K. Psoriasis pathogenesis and treatment［J］. Int J Mol Sci, 2019,20（6）:1475. doi: 10.3390/ijms20061475.
［40］	Suárez⁃Fariñas M, Fuentes⁃Duculan J, Lowes MA, et al. Resolved psoriasis lesions retain expression of a subset of disease⁃related genes［J］. J Invest Dermatol, 2011,131（2）:391⁃400. doi: 10.1038/jid.2010.280.
［41］	Tomalin LE, Russell CB, Garcet S, et al. Short⁃term transcriptional response to IL⁃17 receptor⁃A antagonism in the treatment of psoriasis［J］. J Allergy Clin Immunol, 2020,145（3）:922⁃932. doi: 10.1016/j.jaci.2019.10.041.
［42］	Mehta H, Mashiko S, Angsana J, et al. Differential changes in inflammatory mononuclear phagocyte and T⁃cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab［J］. The Journal of Investigative Dermatology, 2021,141（7）: 1707⁃1718.e9. doi: 10.1016/j.jid.2021.01.005.
［43］	Puig L, Costanzo A, Muñoz⁃Elías EJ, et al. The biological basis of disease recurrence in psoriasis: a historical perspective and current models［J］. Br J Dermatol, 2022,186（5）:773⁃781. doi: 10.1111/bjd.20963.
［44］	Henno A, Blacher S, Lambert C, et al. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque⁃type psoriasis［J］. Br J Dermatol, 2009,160（3）:581⁃590. doi: 10.1111/j.1365⁃2133.2008.08889.x.
［45］	Dressler C, Lambert J, Grine L, et al. Therapeutic patient education and self⁃management support for patients with psoriasis ⁃ a systematic review［J］. J Dtsch Dermatol Ges, 2019,17（7）:685⁃695. doi: 10.1111/ddg.13840.
［46］	Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents［J］. J Am Acad Dermatol, 2019,80（1）:27⁃40. doi: 10.1016/j.jaad.2018.06.057.
［47］	Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis［J］. Lancet, 2021, 397（10281）: 1301⁃1315. doi: 10.1016/S0140⁃6736（20）32549⁃6.
［48］	Chisholm A, Nelson PA, Pearce CJ, et al. Motivational interviewing⁃based training enhances clinicians' skills and knowledge in psoriasis: findings from the Pso Well（®） study［J］. Br J Dermatol, 2017,176（3）:677⁃686. doi: 10.1111/bjd. 14837.
［49］	Blackstone B, Patel R, Bewley A. Assessing and improving psychological well⁃being in psoriasis: considerations for the clinician［J］. Psoriasis （Auckl）, 2022,12:25⁃33. doi: 10.2147/PTT.S328447.
［50］	Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis［J］. J Am Acad Dermatol, 1989,20（1）:53⁃63. doi: 10. 1016/s0190⁃9622（89）70007⁃4.

[1]	Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell-derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220881-e20220881.
[2]	Ye Hui, Deng Shilin, Liang Jingyao, Zhang Xibao. Correlations between the control of atopic dermatitis recurrence and tissue-resident memory T cells [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240192-e20240192.
[3]	Chen Jiaqi, Zhang Jin, Tang Jun. Relationships between coronavirus disease 2019 and psoriasis [J]. Chinese Journal of Dermatology, 2025, 58(1): 84-88.
[4]	Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52.
[5]	Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75.
[6]	Qiao Jiaxi, Xia Ping, Chen Liuqing. Analysis of dermoscopic and reflectance confocal microscopic features of psoriatic lesions before and after treatment with secukinumab [J]. Chinese Journal of Dermatology, 2024, 57(9): 825-829.
[7]	Lin Ziyuan, Pang Tianyi, Wu Jingwen, Jin Hui, . Role of polycyclic aromatic hydrocarbons in the occurrence and development of inflammatory skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(8): 765-769.
[8]	Song Yuqing, Yang Nan, Liu Linlin, Feng Ziyi, Han Shixin, Zhou Meijuan. Dermabrasion for the treatment of familial benign chronic pemphigus: a clinical observation of 6 cases [J]. Chinese Journal of Dermatology, 2024, 57(8): 743-746.
[9]	Dou Jinfa, Wang Jianbo, Zhang Shuai, Li Jianguo, Liu Hongwei, Zhang Shoumin. Analysis of changes in disease status and their influencing factors in patients with moderate to severe plaque psoriasis receiving biologic therapy during the coronavirus disease 2019 pandemic: a single-center cross-sectional study [J]. Chinese Journal of Dermatology, 2024, 57(8): 739-742.
[10]	Sui Changlin, Chang Xiao, Zhao Qi, Zhu Wei. Psoriasis induced by anti-tumor targeted therapy and immunotherapy [J]. Chinese Journal of Dermatology, 2024, 57(6): 570-574.
[11]	Zhang Yuanwen, Sun Congqian, Pan Wendong. Off-label clinical application of botulinum toxin in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(5): 471-475.
[12]	Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478.
[13]	Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents [J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482.
[14]	Hu Mengyao, Li Min, Chen Sihan, Wei Xuecui, Chen Yujie, Xu Song, Chen Xu, . Different regulatory effects of S100A8/A9 expressed by keratinocytes in three common inflammatory skin injury modes [J]. Chinese Journal of Dermatology, 2024, 57(5): 435-444.
[15]	China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417.

Biologics for the treatment of psoriasis relapse: current status

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［50］

Related Articles 15

Metrics

Comments

Recommended 10